Dashboard
Manage Tickers

LGND LIGAND PHARMACEUTICALS INC

Nasdaq ligand.com


$ 190.87 $ -0.07 (-0.04 %)    

Monday, 03-Nov-2025 15:59:55 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 631.41 $ 3.01 (0.48 %)
DIA $ 473.01 $ -2.20 (-0.46 %)
SPY $ 682.75 $ 1.28 (0.19 %)
TLT $ 89.66 $ -0.55 (-0.61 %)
GLD $ 367.20 $ 0.66 (0.18 %)
$ 191.24
$ 191.31
$ 136.00 x 5
$ 195.77 x 15
$ 183.91 - $ 193.02
$ 93.58 - $ 194.44
269,350
na
3.75B
$ 1.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-24-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 03-01-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 02-28-2017 12-31-2016 10-K
36 11-15-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 02-26-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

oppenheimer-maintains-outperform-on-ligand-pharmaceuticals-raises-price-target-to-250
Oppenheimer Maintains Outperform on Ligand...
11/03/2025 15:47:16

Oppenheimer analyst Trevor Allred maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price targ...

ligands-captisol-technology-powers-new-fda-approved-lasix-onyu-for-at-home-edema-treatment-in-heart-failure-patients
Ligand's Captisol Technology Powers New FD...
10/09/2025 11:16:10

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner SQ Innovation Inc. has received approval fro...

arecor-and-ligand-pharmaceuticals-sign-royalty-and-technology-access-deal-for-at220-and-at292-worth-up-to-11m
Arecor And Ligand Pharmaceuticals Sign Roy...
09/25/2025 06:54:40

Co-development Agreement with US Insulin Pump Device Company for AT278 and Sale of Royalty and Technology Access Fees for up to...

oppenheimer-maintains-outperform-on-ligand-pharmaceuticals-raises-price-target-to-190
Oppenheimer Maintains Outperform on Ligand...
09/03/2025 14:43:19

Oppenheimer analyst Trevor Allred maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price targ...

what-analysts-are-saying-about-ligand-pharmaceuticals-stock
What Analysts Are Saying About Ligand Phar...
09/02/2025 22:01:24

benchmark-maintains-buy-on-ligand-pharmaceuticals-raises-price-target-to-175
Benchmark Maintains Buy on Ligand Pharmace...
09/02/2025 13:44:50

Benchmark analyst Robert Wasserman maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target fro...

hc-wainwright--co-maintains-buy-on-ligand-pharmaceuticals-raises-price-target-to-206
HC Wainwright & Co. Maintains Buy on Ligan...
08/28/2025 16:34:15

HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the pr...

reported-earlier-ligand-pharmaceuticals-prices-400m-075-convertible-senior-notes-due-2030-in-private-placement-to-qualified-institutional-buyers
Reported Earlier, Ligand Pharmaceuticals P...
08/12/2025 07:28:57

ligand-pharmaceuticals-to-offer-400m-convertible-senior-notes-due-2030-in-a-private-placement
Ligand Pharmaceuticals To Offer $400M Conv...
08/11/2025 11:15:47

rbc-capital-maintains-outperform-on-ligand-pharmaceuticals-raises-price-target-to-185
RBC Capital Maintains Outperform on Ligand...
08/08/2025 18:17:44

RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price targ...

ligand-pharmaceuticals-raises-fy2025-adj-eps-guidance-from-600-625-to-670-700-vs-612-est-raises-fy2025-sales-guidance-from-180000m-200000m-to-200000m-225000m-vs-194021m-est
Ligand Pharmaceuticals Raises FY2025 Adj E...
08/07/2025 11:03:18

25 Financial GuidanceLigand is increasing its 2025 full year financial guidance. The Company now expects total revenue of $200 ...

ligand-pharmaceuticals-q2-adj-eps-160-beats-142-estimate-sales-47627m-beat-43870m-estimate
Ligand Pharmaceuticals Q2 Adj. EPS $1.60 B...
08/07/2025 11:02:32

Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.60 per share which beat the analyst consensus estimate o...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

Core News & Articles
Orchestra BioMed Secures $111M From Medtro...
08/05/2025 11:14:13

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company acce...

Core News & Articles
Orchestra BioMed Secures $70M In New Capi...
07/31/2025 20:39:10

oppenheimer-maintains-outperform-on-ligand-pharmaceuticals-raises-price-target-to-162
Oppenheimer Maintains Outperform on Ligand...
07/30/2025 13:39:19

Oppenheimer analyst Trevor Allred maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price targ...

pelthos-therapeutics-launches-first-at-home-prescription-gel-for-highly-contagious-skin-disease
Pelthos Therapeutics Launches First At-Hom...
07/10/2025 12:13:33

Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little a...

Core News & Articles
Ligand Pharm's Partner Pelthos Therapeutic...
07/10/2025 12:09:22

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE:PTHS) has co...

verona-pharma-rhythm-pharmaceuticals-aes-and-other-big-stocks-moving-higher-on-wednesday
Verona Pharma, Rhythm Pharmaceuticals, AES...
07/09/2025 15:06:14

Core News & Articles
Reported July 3, 2025: Pelthos Therapeutic...
07/07/2025 15:06:59

- SEC Filing

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION